Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007778.pdf
0001179110-19-007778.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007779.pdf
0001179110-19-007779.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007732.pdf
0001179110-19-007732.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007733.pdf
0001179110-19-007733.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007731.pdf
0001179110-19-007731.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-005464.pdf
0001558370-19-005464.rtf
0001558370-19-005464.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-005447.pdf
0001558370-19-005447.rtf
0001558370-19-005447.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-004566.pdf
0001558370-19-004566.rtf
0001558370-19-004566.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-19-004709.pdf
0001558370-19-004709.rtf
0001558370-19-004709.xls
EX-101.INS - EX-101.INS
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

 View HTML
0001558370-19-003477.pdf
0001558370-19-003477.rtf
0001558370-19-003477.xls